The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0206 ET - AstraZeneca has released promising data for pipeline drugs outside its core oncology business that seem underrated by the market, Bernstein analysts say in a research note. Non-oncology drugs account for nearly two-thirds of Bernstein's estimate for the U.K. pharmaceutical company's sales growth over the next five years, the analysts say. Upcoming data for AstraZeneca's Wainua drug in a trial for transthyretin amyloid cardiomyopathy--a heart disease--and for experimental cholesterol treatment AZD0780 could be key, the analysts add. The company estimates annual peak sales for each drug to top $5 billion and Bernstein says the targets are credible. Moreover, a recent late-stage study of its tozorakimab drug candidate for smokers' cough seems to vindicate AstraZeneca's approach of developing potentially the best--rather than first--of its class of medicines, Bernstein notes. (adria.calatayud@wsj.com)EBR Systems aimed to raise US$108 million at 38 Australian cents a share. "EBR Systems Clears Stock Overhang With Capital Raise -- Market Talk," at 0035 GMT, misstated the amount as 0.38 Australian cents a share.
2035 ET - EBR Systems' capital raise significantly reduces risks around its plans to scale up the WiSE medical technology, but it was markedly different than Bell Potter's expectations. EBR Systems aimed to raise US$108 million at 38 Australian cents a share. Bell Potter had anticipated a US$100 million raise at A$0.63/share. The gap reflects the sharp decline in EBR Systems' share price over the past couple months as the market waited for it to start the funding round, Bell Potter says. EBR aims for this to be last funding round before it reaches breakeven. "This raising should serve as a cathartic event and clear the overhang from the share price," says analyst Martyn Jacobs. Bell Potter retains a buy call and A$2.00/share price target. EBR Systems is downs 11% at A$0.39. (david.winning@wsj.com; @dwinningWSJ) Corrections & Amplifications
This market talk item was corrected at 0048 GMT to reflect EBR Systems aimed to raise US$108 million at 38 Australian cents a share. The original version misstated the amount as 0.38 Australian cents a share.
(END) Dow Jones Newswires
June 05, 2026 12:20 ET (16:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments